April 27, 2017 / 12:02 PM / 3 months ago

BRIEF-Rigel announces Tavaliss as proprietary name for Fostamatinib in the U.S.

1 Min Read

April 27 (Reuters) - Rigel Pharmaceuticals Inc:

* Rigel announces Tavalisse™ as proprietary name for Fostamatinib in the united states

* Says in addition, Rigel has applied to u.s. Patent and trademark office to obtain federal registration of tavalisse mark

* Rigel pharmaceuticals inc - Rigel has applied to u.s. Patent and trademark office to obtain federal registration of tavalisse mark Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below